Related Experiment Video
Updated: Mar 21, 2026

Intrastriatal Injection of Autologous Blood or Clostridial Collagenase as Murine Models of Intracerebral Hemorrhage
Published on: July 3, 2014
Management of intracerebral hemorrhage--use of statins
Edward T Van Matre1, Deb S Sherman2, Tyree H Kiser3
1Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, CO, USA.
Insights
Statins may increase intracerebral hemorrhage (ICH) risk but also improve outcomes post-ICH. This review examines statin therapy
Area of Science:
- Neurology
- Pharmacology
Background:
- Intracerebral hemorrhage (ICH) causes significant disability and death.
- Statins are crucial for preventing ischemic cardiovascular and cerebrovascular events.
- Some studies suggest statins may increase ICH risk, possibly due to cholesterol reduction and pleiotropic effects.
Purpose of the Study:
- To review the pharmacologic effects of statins in relation to ICH risks and benefits.
- To evaluate current literature on statin therapy's impact on ICH patient outcomes.
- To guide clinical decisions regarding statin use in ICH patients.
Main Methods:
- Literature review of pharmacologic effects of statins.
- Analysis of studies investigating statin therapy and ICH outcomes.
- Evaluation of evidence regarding statin initiation, continuation, or discontinuation in ICH.
Main Results:
- Statins' cholesterol-lowering and pleiotropic effects may influence ICH risk.
- Conflicting evidence exists regarding statin use post-ICH, with some studies suggesting benefits.
- Lack of robust prospective trials complicates clinical decision-making.
Conclusions:
- Statin therapy presents a complex risk-benefit profile in intracerebral hemorrhage.
- Further well-designed prospective trials are needed to clarify statin's role in ICH.
- Clinicians must weigh potential risks against possible benefits when managing statin therapy in ICH patients.
Abstract:
Intracerebral hemorrhage (ICH) is a neurologic injury resulting in significant morbidity and mortality. Statins play a significant role in primary and secondary prevention of cardiovascular and cerebrovascular ischemic events. Despite clear benefits of statins in ischemic stroke, post hoc analyses of some studies suggest there may be a link between statin therapy and development of ICH. Direct pharmacologic effects of decreased serum levels of total cholesterol and low-density lipoproteins in conjunction with pleiotropic effects are thought to be linked to this possible increase in ICH risk. In the face of the potential of statins to increase the risk of ICH, recent evidence suggests that statins may also have beneficial effects on patient outcomes when continued or initiated following an ICH. This discordance in findings and the overall lack of well-designed prospective clinical trials increase the complexity of clinical decision making when utilizing statin therapy in patients with, or at risk for, ICH. This review evaluates the pharmacologic effects of statin therapy and describes how these effects translate to both risks and benefits in ICH. The current literature regarding the effects of statin therapy on clinical outcomes in ICH is evaluated to help guide clinicians with decisions regarding initiation, continuation, or discontinuation of statin therapy in patients with ICH.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Acute Coronary Syndrome IV: Interprofessional Care
Venous Thrombosis III: Interprofessional Care
Atherosclerosis IV: Nursing Management
Venous Thrombosis IV: Nursing Management

